Clinical Trial: Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial (China)

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133947

Registration Time: 2026/10/09

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=346578

Published by HT Digital Content Services with permission from Health Daily Digest....